Professor Murray Norris AMChildren’s Cancer InstituteCancer Council NSW Funding: $2,249,946Funding duration: 2016-2020
Despite the success in treating childhood leukaemia, it still remains one of the most common causes of death from disease in children in Australia.
The aim of this 5 year program is to increase survival rates of children with Acute Lymphoblastic Leukaemia (ALL) and ultimately develop prevention strategies.
Specifically, this research focuses on developing new molecular targeted therapies for children with ALL which improve outcomes and have limited side effects.
Molecular therapies have enormous potential to significantly improve survival rates and quality of life for childhood survivors as they directly target the leukaemia cells while reducing the impact on healthy cells.